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Urothelial Bladder Cancer (UBC) has a global prevalence of 2.7 million [1], with around 
429,000 new cases diagnosed worldwide in 2014, with 165,000 patients deaths each year 
[2]. At presentation over three quarters of UBCs will be confined to the mucosa or lamina 
propria (Non-Muscle-Invasive Bladder Cancer, NMIBC: stages Ta/T1/Tis), whereas the 
remainder are more invasive penetrating the underlying detrusor muscle and beyond with 
an ability to metastasise (Muscle-Invasive Bladder Cancer, MIBC: stages T2-T4) [3]. Of those 
patients with NMIBC, around 40% eventually progress to MIBC, of whom 20% will die from 
metastatic disease [4]. Advanced metastatic MIBC has a very poor 5-year survival rate of 
around 5%, compared to 80-90% for NMIBC [4]. Unfortunately, an absence of ‘tailored’ 
therapies for metastatic UBC is one contributing factor to the lack of significant 
improvement in outcomes for the last 30 years, with median survival rates remaining at 15 
months. An unmet need exists for the development of efficacious and well tolerated 
therapies for metastatic UBC to improve the guarded prognosis and dismal survival still seen 
in these patients. 
In 2011, Hanahan and Weinberg implicated the role of immune evasion in cancers to allow 
tumourigenic progression [5]. The developing field of immunotherapeutics has since aimed 
to target this notion, utilising monoclonal antibody therapy to block T cell immunological 
checkpoints in the management of UBC. In particular, members of the Programmed Cell 
Death Protein 1 (PD-1) / Programmed Death Ligand 1 (PD-L1) signalling axis have been 
promising targets, with multiple studies demonstrating that higher levels of PD-L1 
expression on tumour cells may facilitate tumour progression and promote tumour 
invasiveness and metastatic progression [6-8]. These results have led to breakthrough 
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therapy designation by the FDA for the anti-PD-L1 antibody MPDL3280A in metastatic UBC 
[9]. 
In this paper we discuss the mechanism for immune-evasion by UBC cells using the PD-
1/PD-L1 signalling axis; we also evaluate the use of anti-PD-L1 therapy in metastatic UBC, 
and its viability as a future clinical treatment. 
 
The PD-1/PD-L1 signalling axis impedes an effector T-lymphocyte response towards 
tumour cells   
The PD1 protein is an inhibitory transmembrane receptor expressed primarily on the surface 
of CD4+ and CD8+ T lymphocytes, but is also present on B lymphocytes and NK cells. Upon 
interaction with its cognate ligands, PD-L1 (B7-H1) or PD-L2 (B7-DC), it plays a fundamental 
role in regulating T-cell proliferation and suppressing elevated cytotoxic T-cell activity in 
peripheral tissues upon infection, thus acting as a tolerance mechanism for the prevention 
of autoimmunity [10]. As such, the PD-1/PD-L1 pathway has been recognised within the 
tumour microenvironment as a method of immune-evasion. The upregulation of PD-L1 
expression on the surface of UBC cells causes subsequent evasion of a T-cell effector 
response which aids tumour invasiveness. Furthermore, increased expression of PD-L1 is 
associated with a higher tumour grade and poorer survival rates [6-8]. 
Currently, two models exist implicating the method of PD-L1 upregulation on tumour cells: 
innate immune resistance and adaptive immune resistance [11]. The innate immune 
resistance mechanism is activated upon constitutive oncogenic signalling inducing PD-L1 
expression on tumour cell surface. The adaptive immune resistance mechanism occurs in 
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response to a previously mounted antitumor immune response due to cytokine production. 
Innate immune resistance relies upon constitutive oncogenic signalling in the tumour cell 
which drives the upregulation of PD-L1 on tumour cells. Parsa et al first demonstrated PD-L1 
expression on tumour cells upon constitutive activation of the AKT signalling pathway, and 
more specifically this expression was enhanced as a result of a deletion or silencing of the 
tumour suppressor, PTEN [12]. However, this was demonstrated only in vitro using a glioma 
cell line, thus results cannot be directly applied to UBC. Despite this, loss of PTEN is a key 
carcinogenic process demonstrated in MIBC cell lines. Mutated PTEN inactivates mTOR 
leading to dysregulated AKT activation which ultimately upregulates PD-L1 in these cells 
[13]. In contrast, in the adaptive mechanism, PD-L1 expression occurs only in response to a 
previously propagated antitumour immune response. This relies strongly on PD-L1 
expression occurring in response to cytokine stimulation; in particular, interferon gamma 
(IFN-γ) production from the surrounding epithelial and stromal microenvironment [8].  Liu 
et al demonstrated that the IFN-γ and TLR ligands activate PD-L1 expression via a common 
signalling pathway involving Myd88/MEK/ERK/STAT1 [14]. Furthermore, synthetically 
blocking ERK signalling via an ERK inhibitor leads to inhibition of PD-L1 expression and also 
functionally demonstrates increased Cytotoxic Lymphocyte (CTL) killing of UBC cells, 
reiterating the importance of this pathway in activating the PD-1/PD-L1 axis [15]. Ultimately, 
the effector functions of PD-1/PD-L1 interaction are mediated through dephosphorylation 
and inhibition of hundreds of interconnecting downstream signalling kinase pathways 
through recruitment of SHP250 phosphatase [16]. This inhibits signalling events 
downstream of the TCR, including PI3K/Akt activation, limiting T-cell proliferation, 
promoting the differentiation of CD4+ T cells into Fox P3+ Treg cells and governing tumour 
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cells’ resistance to cytotoxic T lymphocyte attack [11]. The individual molecular details of 
these signalling pathways are beyond the scope of this literature review. 
 
PD-L1 expression levels are associated with increased tumour staging and aggressiveness 
The expression of PD-L1 on UBC cells facilitates evasion of immunological T-cell targeting, 
resulting in tumour propagation. It has therefore been postulated that through quantifying 
the amount of PD-L1 within a tumour sample, it may predict the extent of tumour 
aggressiveness.  
Nakanishki first analysed and identified the percentage of PD-L1 expression (B7-H1) on UBC 
cells, showing a statistically significant association with tumour grade (p = 0.01) and stage (p 
= 0.031) [6]. Grade 1 tumours demonstrated 8.12% PD-L1 expression (mean:  8.12 SD+/- 
0.05) compared to 26.1% expression (mean: 25.6 SD +/- 0.09) in grade 3 tumours. 
Additionally, Ta tumours and CIS demonstrated 16.4% PD-L1 expression (mean: 16.4 SD+/- 
0.12) compared to 34.7 % (mean: 34.7 SD+/- 0.13) in T4 tumours.  Inman and colleagues 
confirmed this finding in a cohort of 280 UBC samples evaluated for PD-L1 expression by 
immunohistochemistry (IHC), demonstrating that stage progression was strongly associated 
with the extent of PD-L1 expression [7]. They showed that 28% of tumour specimens stained 
positive for PD-L1 (defined as plasma membrane staining of greater than 1% of tumour 
cells), of which 7% of pTa tumours had PD-L1 positivity in comparison to 30% of T3/4 
tumours. Univariate statistical modelling showed that PD-L1 expression had an association 
with higher grade tumours (OR 2.4 [95% CI: 1.2-4.72]) (p= 0.09). However, there are 
limitations to this study. Firstly, it has been demonstrated that there is a disparity in PD-L1 
expression between fresh resected material and historic paraffin-embedded samples, and 
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this could account for the lack of PD-L1 positive tumours in this study [8]. Furthermore 
retrospective studies are prone to selection bias, and combined with discrepancies in 
defining PD-L1 positivity between studies (>5% vs >1%), this may not be truly representative 
of PD-L1 expression in UBC. 
Bellmunt et al recently demonstrated a lack of association of PD-L1 with tumour stage or 
outcome in NMIBC and MIBC (PD-L1 expression of 41.8% vs 30%, respectively, p=0.53]).[9] It 
is important to note that due to the focal nature of PD-L1 expression within tumours 
combined with considerable intratumour heterogeneity in UBC, the three different sampling 
cores utilised in the study may not have been adequate. 
A meta-analysis by Zhang in 2015, which examined the expression profiles of PD-L1 in a 
range of epithelial cancers including UBC, demonstrated that UBCs did not show a 
significant  increase in overall survival in tumours which were PD-L1 negative (HR 1.06, 95% 
CI 0.71–1.58, p=0.761) [16]. Conversely, comparing PD-L1 negative tumours with PD-L1 
positive tumours showed increased overall survival in all of the epithelial cancers in the 
meta-analysis (HR 1.81, 95% CI 1.33-2.46, p<0.001). Overall, they concluded that there was 
an 81% increase in risk for all time mortality associated with PD-L1 positivity. By combining 
PD-L1 expression and outcome data from this group of histologically and morphologically 
similar tumour types, the authors have potentially identified an overall significant effect 
between PD-L1 expression and tumour stage and survival. However, the current lack of 
available data in UBC and relatively small non-representative samples may be masking a 
genuine association between PD-L1 expression and important clinical variables, limiting the 
identification of statistically viable relationships. Furthermore, the lack of prospective data 
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and the lack of standardised antibodies and cut-offs implies that a valid conclusion cannot 
yet be made. 
Anti-PDL1 therapy can enhance intratumoural immune responses leading to tumour 
regression in metastatic UBC 
Antibody targeting of PD-L1 expressed on tumour cells primarily acts through inhibiting 
molecular binding to PD-1, thus mobilising tumour-specific CTLs to mediate destruction of 
PD-L1 expressing tumour cells. The increased expression of PD-L1 on tumour cells in a 
diverse range of cancers has generated an important rationale for the capacity of 
monoclonal antibody blockade of this pathway to enhance intratumoural immune 
responses, and prevent invasion and therefore progression [11]. 
Iwai et al functionally demonstrated the anti-tumorigenic effects of inhibiting the PD-1/PD-
L1 axis. Using an in vivo modelling experiment with PD-1 knockout mice and subcutaneous 
injection of a PD-L1 positive J558L myeloma cell line, they showed that there was complete 
suppression of tumour growth when compared to mice expressing normal PD-1 [17]. 
Tumour volumes reached up to 6800mm3 in the PD-1 +/+ mice 18 days post inoculation, 
compared to completely suppressed growth in the knockout mice.  
In the clinical setting, Brahmer demonstrated the significant efficacy associated with anti-
PD-L1 therapy in advanced metastatic cancer. In a group of 160 patients with renal cell, 
colorectal, ovarian and pancreatic cancers, they demonstrated durable tumour regression 
effects in all of the cancer subgroups with objective responses in 6 to 17% of patients [10]. 
In addition, there was prolonged stabilisation of disease at 24 weeks in 12-41% patients. 
These results demonstrate the potentially considerable clinical benefits of anti-PD-L1 
therapy in cancer patients with a poor prognosis. The study also highlighted the low toxicity 
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associated with anti-PD-L1 therapy with 91% of drug-related adverse events being low 
grade, of which fatigue and loss of appetite were most common; treatment-related grade 3 
or 4 events were observed in 19 out of 207 patients. Thus, the therapy appears to be well-
tolerated in advanced metastatic cancer. 
The recent results of an expanded phase I trial using MPDL3280A (anti-PD-L1) in a heavily 
pre-treated advanced UBC population similarly showed promising clinical outcomes [9]. In 
67 patients after 6 weeks of follow-up, 43% of patients with positive PD-L1 expression 
achieved an objective response compared to 11% of patients with negative PD-L1 
expression. In addition, 7% of the positive PD-L1 patients achieved a complete response at 6 
weeks after treatment, reinforcing the efficacious effect of anti-PD-L1 therapy in patients 
with advanced disease who have previously failed chemotherapy. However, the response to 
MPDL3280A was more associated with PDL-1 expression in tumour infiltrating immune cells 
(TIICs) (p<0.026) than expression in UBC tumour cells (p<0.93). The role of TIICs and their 
PD-L1 expression may thus provide an important mechanism for determining the likelihood 
of response to anti-PD-L1 therapy, and may be utilised as a predictive biomarker. However, 
further work is required since TIICs were characterised by morphology only; we suggest 
greater molecular characterisation is warranted through co-immunostaining for CD11b, 
Granulocyte receptor 1 and CD3 to definitively confirm their origin. Furthermore, the small 
pool of PD-L1 negative patients who responded to therapy raises a concern for the 
implications of excluding PD-L1 negative patients and henceforth excluding potential 
responders to therapy. PD-L1 positive and negative groups were also not well balanced (7 
and 58 patients, respectively) which questions the overall power of this study. 
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Future clinical implications for anti-PD-L1 therapy  
Deng et al recently reported the effectiveness of anti-PD-L1 used as a combinational therapy 
with high dose ionising radiotherapy (IR). They noted that PD-L1 expression was induced in 
tumour cells after IR and so could represent a potential mechanism for immune evasion 
(and resulting in high tumour relapse rates after treatment)[18]. Combining anti PD-L1 with 
IR showed a statistically significant restriction in tumour growth compared to IR alone after 
31 days: IR monotherapy tumour size: 402.8 ± 76.73 mm vs. IR + anti PD-L1 tumour size: 
25.59 ± 10.26 mm) (p = 0.0002). These results demonstrate a 16-fold difference in tumour 
size despite similar baseline growth characteristics prior to treatment. IR appeared to slow 
tumour progression whereas the combinational therapy of IR and anti-PD-L1 dramatically 
restricted tumour growth and enhanced the effects of IR. Additionally, anti-PD-L1 therapy 
alone showed modest tumour size of 587.3 ± 169.1 mm, although less effective than IR as a 
monotherapy. This indicates the efficacy and clinical benefit of this treatment is best suited 
as combinational therapy and may require IR to dynamically enhance the levels of PD-L1 
expression to a clinically efficacious threshold which then can be inhibited, thus 
downregulating the numerous associated signalling pathways which drive tumour 
progression. However, these results were trialled using a mammillary carcinoma cell line, 
which may not be fully characteristic of the cytokine milieu and behaviour of UBC cells. 
Despite this, radiotherapy is a common treatment for MIBC and so further investigation is 
warranted to determine whether PD-L1 expression is induced in UBC after IR and whether 
there are potential therapeutic benefits of combinatorial anti-PD-L1 therapy. 
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We have discussed the importance of anti PD-L1 therapy in targeting advanced metastatic 
MIBC. However, there may also be utility in the NMIBC setting to prevent tumour 
progression. Inman first characterised Carcinoma in situ (CIS) as having the highest levels of 
PD-L1 expression, with a greater than 10% increase in PD-L1 positivity than late stage pT3/4 
UBC tumour cells[7]. This is of paramount importance as approximately 50% of CIS patients 
experience stage progression.  Intravesical BCG immunotherapy combined with aggressive 
endoscopic removal does not, unfortunately, confer life-long immunity, with BCG failure 
occurring on average after 5 years. It appears therefore, that BCG’s initial 
immunosuppressive mechanism against CIS is overcome by enhanced intratumoural PD-L1 
expression and infiltrating lymphocytes. 
Although 45% of CIS lesions are PD-L1 positive, there is a low median intratumoural 
expression of just 5% of cells [7]. However, CIS patients who failed BCG had a 20-fold 
increase in PD-L1 expression. This highlights the importance of the PD1/PD-L1 axis in driving 
tumour progression and in developing an adaptive resistance mechanism to BCG therapy, 
and the potential for anti-PD1/PD-L1/BCG combination therapy. There is an urgent need for 
further studies to elucidate a mechanistic involvement of PD-L1 in BCG failure, and to 
explore whether this can be exploited. 
 
Conclusion 
Appreciating the molecular mechanisms underpinning PD-1/PD-L1 signalling in UBC is 
imperative in highlighting the rationale behind its use in immunotherapy. Empirical evidence 
in a range of cancers suggests PD-L1 expression may be induced upon a complex interplay 
between constitutive oncogenic signalling and inflammatory cytokine stimulation from the 
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tumour microenvironment [13-15]. This background is mechanistically important in 
characterising the behaviour of UBC cells which may be responsible for propagating tumour 
invasiveness and treatment resistance [19]. Henceforth, it identifies a new, 
pharmacologically tailored therapeutic target to be utilised in patients who are already 
chemo/radiotherapy resistant and are in the late stages of aggressive or metastatic MIBC.   
We have also discussed the implications of PD-L1 status and whether it negatively associates 
with reduced survival and increased tumour aggressiveness. There is a current discordance 
in medical literature about whether PD-L1 expression is responsible, with statistically 
significant data existing for both viewpoints. The current available literature in bladder 
cancer is primitive and has too many confounding factors. We suggest that further 
observational studies are required using larger sample populations with a consistent 
methodology for assessing PD-L1 status. This will involve the development of a standardised 
PD-L1 antibody for IHC, agreeing a PD-L1 expression cut-off value, and assessing whole 
tumour sections (instead of tumour core biopsy samples) to account for the focal nature of 
PD-L1 expression patterns. 
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Furthermore, the use of anti PD-L1 therapy has identified that a small responsive pool of PD-
L1 negative patients (15%) achieved objective responses to therapy [9]. This implies that 
either there was a failure to identify these patients as PD-L1 positive, or that further 
underlying mechanisms have resulted in a molecular response to therapy. We hypothesise 
that infiltrating lymphocytes in the tumour microenvironment which are PD-L1 positive may 
be the most likely reason behind this observation. This raises concerns as excluding PD-L1 
negative patients may exclude potential responders to therapy. 
It also re-evaluates the current viewpoint on PD-L1 screening and whether it is even 
necessary: should pre-treatment PD-L1 assessment be abolished or be expanded to 
encompass the characterisation of TIL PD-L1 status? Furthermore, current studies have only 
characterised PD-L1 expression on primary UBCs and do not account for metastases; this 
should be further evaluated through biopsies of involved lymph nodes and distant 
metastases. The promising results of Powles’ phase I anti-PD-L1 therapy in UBC have 
resulted in provisional FDA approval [9]. We await the results of the phase II trial which is 
currently underway. 
We also report on the favourable toxicity profile associated with anti-PD-L1 therapy. 
Considering that the majority of UBC patients are over 70 years old, with an estimated 40% 
with some level of renal impairment, there is significant importance in ensuring that 
treatments are well tolerated and can generate objective tumour responses without a 
trade-off for quality of life. Further longitudinal studies are also warranted to ensure safety 
and tolerability for patients in the longer term and to ensure no autoimmune toxicity issues 
arise. 
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Finally, the future indications for anti-PD-L1 therapy may extend to BCG-resistant NMIBC. 
This has significant economic incentives due to the patient burden and healthcare costs of 
NMIBC and the globally limited supply of BCG [20]. We postulate that anti-PD-L1 may 
circumvent BCG resistance mechanisms and prevent the progression to MIBC and 
metastatic disease. 
In conclusion, anti-PD-L1 is a highly promising therapy in UBC. The wealth of upcoming 
clinical trials highlights the global scientific enthusiasm surrounding this therapeutic 
approach which may dramatically improve the lives of UBC patients in the near future. 
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